Custom Antibody Market worth $1.13 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global custom antibody market will grow from USD 0.72 billion in 2026 to USD 1.13 billion by 2031, a 9.5% CAGR. North America held 41.8% of the market in 2025, while antibody development services held 53.6%; monoclonal antibodies are forecast to grow at a 10.0% CAGR. The report cites rising outsourcing, biologics research, and adoption of recombinant and AI-enabled discovery technologies, and notes Agilent’s March 2026 acquisition of Biocare Medical.

Analysis

This is a market-research forecast, not evidence of booked demand. The headline growth rate is a weak basis for repricing diversified life-science suppliers: the relevant question is whether custom work converts into recurring production, validation, and outsourcing revenue at attractive economics. If that mix shift occurs, it favors providers with integrated discovery-to-production workflows over one-off antibody generation, but it may also intensify competition on turnaround time and price from specialist providers such as GenScript.

Agilent’s Biocare Medical deal could strengthen its pathology and IVD antibody offering, but the article does not establish incremental sales, cross-selling, or returns; do not extrapolate the acquired portfolio into broad custom-antibody share gains. The claimed market concentration likewise does not establish pricing power, particularly as customers can outsource to specialists or build capabilities internally. Any impact on A, TMO, BIO, or MRK is likely immaterial to consolidated results absent company-specific disclosure. The Solventum reference is about downstream-processing workflow adjacency, not proof of custom-antibody exposure or a direct market-share gain.

Near term, this promotional forecast is unlikely to be a durable catalyst. Over 1–3 months, monitor company disclosures for service growth, backlog/outsourcing wins, and acquisition contribution; over 6–18 months, recombinant and integrated services could shift value toward scalable platforms. Contrarian point: the report’s precise growth estimate may create more confidence than its methodology warrants, while the more investable signal is recurring revenue and realized margins—not market size. Thesis weakens if providers report flat service demand, discounting, or no conversion of platform investment into revenue.

Key Decisions for Investors

• No trade on the forecast alone; treat the release as low-quality thematic evidence rather than a company-specific earnings catalyst.
• Keep A, TMO, BIO, and MRK on watchlists, but require reported service-line growth, recurring-contract evidence, or quantified contribution before attributing material upside to custom antibodies.
• For Agilent, track Biocare’s disclosed contribution and any evidence of cross-selling into pathology/IVD workflows; avoid treating the acquisition as proof of custom-antibody market-share gains.
• Watch specialist providers, including GenScript, for pricing or capacity signals that could pressure integrated vendors; revisit the thesis if earnings disclosures show sustained outsourcing growth with improving service economics.